These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|
Delaware
|
|
77-0390628
|
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification Number)
|
|
308 Dorla Court, Suite 206
|
|
|
|
Zephyr Cove, Nevada
|
|
89448
|
|
(Address of principal executive offices)
|
|
(Zip Code))
|
|
Large accelerated filer
x
|
Accelerated filer
o
|
Non-accelerated filer
o
|
Smaller reporting company
o
|
|
(Do not check if a smaller reporting company)
|
|||
|
|
|
Page
|
|
1
|
||
|
|
Item 1 —
Financial Statements.
|
1
|
|
|
1
|
|
|
|
2
|
|
|
|
2
|
|
|
|
3
|
|
|
|
4
|
|
|
|
12
|
|
|
|
16
|
|
|
|
Item 4 —
Controls and Procedures
|
16
|
|
17
|
||
|
|
Item 1 —
Legal Proceedings
|
17
|
|
|
Item 1A —
Risk Factors
|
19
|
|
|
Item 6 —
Exhibit
|
26
|
|
27
|
||
|
28
|
||
|
|
March 31,
2014
|
December 31,
2013
|
||||||
|
|
(Unaudited)
|
|
||||||
|
ASSETS
|
|
|
||||||
|
Current assets:
|
|
|
||||||
|
Cash and cash equivalents
|
$
|
13,456
|
$
|
19,173
|
||||
|
Investments available for sale
|
17,486
|
19,815
|
||||||
|
Prepaid expenses - current
|
781
|
357
|
||||||
|
Total current assets
|
31,723
|
39,345
|
||||||
|
Prepaid expenses - non-current
|
3,600
|
—
|
||||||
|
Property and equipment, net
|
47
|
53
|
||||||
|
Total assets
|
$
|
35,370
|
$
|
39,398
|
||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable and accrued liabilities
|
$
|
3,011
|
$
|
1,748
|
||||
|
Income tax liability
|
395
|
395
|
||||||
|
Deferred revenue
|
417
|
667
|
||||||
|
Derivative liability
|
1,726
|
2,564
|
||||||
|
Total current liabilities
|
5,549
|
5,374
|
||||||
|
|
||||||||
|
Commitments and contingencies
|
—
|
—
|
||||||
|
|
||||||||
|
Stockholders' equity:
|
||||||||
|
Preferred stock, par value $0.0001 per share
|
||||||||
|
Authorized: 10,000,000 shares at March 31, 2014, and December 31, 2013, Issued and outstanding: 0 shares at March 31, 2014 and December 31, 2013
|
—
|
—
|
||||||
|
Common stock, par value $0.0001 per share
|
||||||||
|
Authorized: 100,000,000 shares at March 31, 2014 and December 31, 2013, Issued and outstanding: 51,492,237 shares at March 31, 2014, and 51,236,141 shares at December 31, 2013
|
5
|
5
|
||||||
|
Additional paid in capital
|
126,484
|
124,589
|
||||||
|
Accumulated deficit
|
(96,620
|
)
|
(90,533
|
)
|
||||
|
Accumulated other comprehensive loss
|
(48
|
)
|
(37
|
)
|
||||
|
Total stockholders' equity
|
29,821
|
34,024
|
||||||
|
Total liabilities and stockholders' equity
|
$
|
35,370
|
$
|
39,398
|
||||
|
|
Three Months Ended
|
|||||||
|
|
March 31, 2014
|
March 31, 2013
|
||||||
|
Revenue
|
$
|
250
|
$
|
293
|
||||
|
Operating expense:
|
||||||||
|
Research and development
|
347
|
304
|
||||||
|
General, selling and administrative
|
6,856
|
9,518
|
||||||
|
Total operating expense
|
7,203
|
9,822
|
||||||
|
Loss from operations
|
(6,953
|
)
|
(9,529
|
)
|
||||
|
Gain on change in value of derivative liability
|
838
|
1,606
|
||||||
|
Interest income, net
|
30
|
34
|
||||||
|
Loss before taxes
|
(6,085
|
)
|
(7,889
|
)
|
||||
|
Provision for income taxes
|
(2
|
)
|
(2
|
)
|
||||
|
Net loss
|
$
|
(6,087
|
)
|
$
|
(7,891
|
)
|
||
|
Basic and diluted loss per share
|
$
|
(0.12
|
)
|
$
|
(0.15
|
)
|
||
|
Weighted average shares outstanding basic and diluted
|
51,253
|
51,151
|
||||||
|
|
Three Months Ended
|
|||||||
|
|
March 31, 2014
|
March 31, 2013
|
||||||
|
Net loss
|
$
|
(6,087
|
)
|
$
|
(7,891
|
)
|
||
|
Other comprehensive loss, net of tax:
|
||||||||
|
Change in unrealized loss on investments, net of tax
|
(11
|
)
|
(8
|
)
|
||||
|
Total other comprehensive loss, net of tax
|
(11
|
)
|
(8
|
)
|
||||
|
Comprehensive loss
|
$
|
(6,098
|
)
|
$
|
(7,899
|
)
|
||
|
|
Three Months
Ended
March 31, 2014
|
Three Months
Ended
March 31, 2013
|
||||||
|
Cash flows from operating activities:
|
|
|
||||||
|
Net loss
|
$
|
(6,087
|
)
|
$
|
(7,891
|
)
|
||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
|
Depreciation and amortization
|
5
|
17
|
||||||
|
Stock-based compensation
|
1,828
|
1,585
|
||||||
|
Change in value of derivative liability
|
(838
|
)
|
(1,606
|
)
|
||||
|
Changes in assets and liabilities:
|
||||||||
|
Prepaid expenses - current
|
(424
|
)
|
(528
|
)
|
||||
|
Prepaid expenses - non-current
|
(3,600
|
)
|
—
|
|||||
|
Accounts payable and accrued liabilities
|
1,263
|
930
|
||||||
|
Deferred revenue
|
(250
|
)
|
—
|
|||||
|
Net cash used in operating activities
|
(8,103
|
)
|
(7,493
|
)
|
||||
|
Cash flows from investing activities:
|
||||||||
|
Purchase of property and equipment
|
—
|
(4
|
)
|
|||||
|
Purchase of investments
|
(3,383
|
)
|
(12,989
|
)
|
||||
|
Proceeds from sale or maturity of investments
|
5,701
|
18,385
|
||||||
|
Net cash provided by investing activities
|
2,318
|
5,392
|
||||||
|
Cash flows from financing activities:
|
||||||||
|
Proceeds from exercise of options
|
68
|
17
|
||||||
|
Net cash provided by financing activities
|
68
|
17
|
||||||
|
Net decrease in cash and cash equivalents
|
(5,717
|
)
|
(2,084
|
)
|
||||
|
Cash and cash equivalents, beginning of period
|
19,173
|
19,661
|
||||||
|
Cash and cash equivalents, end of period
|
$
|
13,456
|
$
|
17,577
|
||||
| · | Consideration for Past Sales : Consideration related to a licensee’s product sales from prior periods may result from a negotiated agreement with a licensee that utilized our patented technology prior to signing a patent license agreement with us or from the resolution of a litigation, disagreement or arbitration with a licensee over the specific terms of an existing license agreement. We may also receive royalty for past sales in connection with the settlement of patent litigation where there was no prior patent license agreement. These amounts are negotiated, typically based upon application of a royalty rate to historical sales prior to the execution of the license agreement. In each of these cases, since delivery has occurred, we record the consideration as revenue when we have obtained a signed agreement, identified a fixed or determinable price, and determined that collectability is reasonably assured. |
| · | Current Royalty Payments : Ongoing royalty payments cover a licensee’s obligations to us related to its sales of covered products in the current contractual reporting period. Licensees that owe these current royalty payments are obligated to provide us with quarterly or semi-annual royalty reports that summarize their sales of covered products and their related royalty obligations to us. We expect to receive these royalty reports subsequent to the period in which our licensees’ underlying sales occurred. As a result, it is impractical for us to recognize revenue in the period in which the underlying sales occur, and, in most cases, we will recognize revenue in the period in which the royalty report is received and other revenue recognition criteria are met due to the fact that without royalty reports from our licensees, our visibility into our licensees’ sales is limited. |
| · | Non-Refundable Prepaid Fees and Minimum Fee Contracts : For contracts which contain non-refundable prepayment or fixed minimum payments over the remaining term of the license, where we have no future obligations or performance requirements, revenue is generally deferred and recognized over the license term, depending on how and when the revenue recognition process is complete. However, revenue for contracts longer than one year may not be recognized in advance of collections. |
| · | Non-Royalty Elements : Elements that are not related to royalty revenue in nature, such as settlement fees, expense reimbursement, and damages, if any, are recorded as gain from settlement which is reflected as a separate line item within the operating expenses section in the consolidated statements of operations. |
|
Deferred Revenue, December 31, 2013
|
$
|
667
|
||
|
Less: Amount amortized as revenue
|
250
|
|||
|
Deferred Revenue, March 31, 2014
|
$
|
417
|
|
|
March 31, 2014
|
|||||||||||||||||||||||
|
|
|
|
|
|
Cash
|
Investments
|
||||||||||||||||||
|
|
Adjusted
|
Unrealized
|
Unrealized
|
Fair
|
and Cash
|
Available
|
||||||||||||||||||
|
|
Cost
|
Gains
|
Losses
|
Value
|
Equivalents
|
for Sale
|
||||||||||||||||||
|
Cash
|
$
|
6,640
|
$
|
-
|
$
|
-
|
$
|
6,640
|
$
|
6,640
|
$
|
-
|
||||||||||||
|
|
||||||||||||||||||||||||
|
Level 1:
|
||||||||||||||||||||||||
|
Mutual funds
|
141
|
-
|
-
|
141
|
141
|
-
|
||||||||||||||||||
|
Corporate securities
|
10,929
|
1
|
(3
|
)
|
10,927
|
1,858
|
9,069
|
|||||||||||||||||
|
Municipal securities
|
1,996
|
-
|
-
|
1,996
|
513
|
1,483
|
||||||||||||||||||
|
U.S agency securities
|
11,272
|
4
|
(38
|
)
|
11,238
|
4,304
|
6,934
|
|||||||||||||||||
|
|
24,338
|
5
|
(41
|
)
|
24,302
|
6,816
|
17,486
|
|||||||||||||||||
|
Total
|
$
|
30,978
|
$
|
5
|
$
|
(41
|
)
|
$
|
30,942
|
$
|
13,456
|
$
|
17,486
|
|||||||||||
|
|
December 31, 2013
|
|||||||||||||||||||||||
|
|
|
|
|
|
Cash
|
Investments
|
||||||||||||||||||
|
|
Adjusted
|
Unrealized
|
Unrealized
|
Fair
|
and Cash
|
Available
|
||||||||||||||||||
|
|
Cost
|
Gains
|
Losses
|
Value
|
Equivalents
|
for Sale
|
||||||||||||||||||
|
Cash
|
$
|
11,699
|
$
|
-
|
$
|
-
|
$
|
11,699
|
$
|
11,699
|
$
|
-
|
||||||||||||
|
|
||||||||||||||||||||||||
|
Level 1:
|
||||||||||||||||||||||||
|
Mutual funds
|
73
|
-
|
-
|
73
|
73
|
-
|
||||||||||||||||||
|
Corporate securities
|
10,782
|
-
|
-
|
10,782
|
2,325
|
8,457
|
||||||||||||||||||
|
Municipal securities
|
2,173
|
-
|
-
|
2,173
|
665
|
1,508
|
||||||||||||||||||
|
U.S agency securities
|
14,287
|
-
|
(25
|
)
|
14,262
|
4,411
|
9,851
|
|||||||||||||||||
|
|
27,315
|
-
|
(25
|
)
|
27,289
|
7,474
|
19,815
|
|||||||||||||||||
|
Total
|
$
|
39,014
|
$
|
-
|
$
|
(25
|
)
|
$
|
38,988
|
$
|
19,173
|
$
|
19,815
|
|||||||||||
|
March 31, 2014
|
||||||||||||||||
|
Quoted
Prices in
Active
Markets
for
Identical
Assets
|
Significant
Other
Observable
Inputs
|
Significant
Unobservable
Inputs
|
||||||||||||||
|
|
(Level 1)
|
(Level 2)
|
(Level 3)
|
Total
|
||||||||||||
|
Series l Warrants
|
$
|
—
|
$
|
—
|
$
|
1,726
|
$
|
1,726
|
||||||||
|
Total
|
$
|
—
|
$
|
—
|
$
|
1,726
|
$
|
1,726
|
||||||||
|
December 31, 2013
|
||||||||||||||||
|
Quoted
Prices in
Active
Markets for
Identical
Assets
|
Significant
Other
Observable
Inputs
|
Significant
Unobservable
Inputs
|
||||||||||||||
|
|
(Level 1)
|
(Level 2)
|
(Level 3)
|
Total
|
||||||||||||
|
Series l Warrants
|
$
|
—
|
$
|
—
|
$
|
2,564
|
$
|
2,564
|
||||||||
|
Total
|
$
|
—
|
$
|
—
|
$
|
2,564
|
$
|
2,564
|
||||||||
|
|
Three Months Ended
March 31, 2014
|
|
Three Months Ended
March 31, 2013
|
||||||
|
|
Fair Value
Measurements
Using
Significant
Unobservable
Inputs (Level 3)
|
|
Fair Value
Measurements
Using
Significant
Unobservable
Inputs (Level 3)
|
||||||
|
Balance December 31, 2013
|
$
|
2,564
|
Balance December 31, 2012
|
$
|
4,172
|
||||
|
Gain on derivative liability included in net loss
|
(838
|
)
|
Gain on derivative liability included in net loss
|
(1,606
|
)
|
||||
|
Balance March 31, 2014
|
$
|
1,726
|
Balance March 31, 2013
|
$
|
2,566
|
||||
|
Original Number of
Warrants Issued
|
Exercise
Price per Common
Share
|
Exercisable at
December 31,
2013
|
Became
Exercisable
|
Exercised
|
Terminated /
Cancelled /
Expired
|
Exercisable
at March 31, 2014
|
Expiration
Date
|
||||||||||||||||||
|
2,619,036
|
(1) |
$
|
3.59
|
159,967
|
—
|
—
|
—
|
159,967
|
March 2015
|
||||||||||||||||
|
Total
|
159,967
|
—
|
—
|
—
|
159,967
|
|
| (1) | Referred to as our Series I Warrants. |
| ● | Although we have to date entered into a limited number of settlement and license agreements, we may not be successful in entering into further licensing relationships and existing settlement and license agreements may not generate the financial results we expect; |
| ● | Third parties may challenge the validity of our patents; |
| ● | The pendency of our various litigations may cause potential licensees not to do business with us; |
| ● | We face, and we expect to continue to face, intense competition from new and established competitors who may have superior products and services or better marketing, financial or other capacities than we do; and |
| ● | It is possible that one or more of our potential customers or licensees develops or otherwise sources products or technologies similar to, competitive with or superior to ours. |
| ● | New legislation, regulations or rules related to obtaining patents or enforcing patents could significantly increase our operating costs and decrease our revenue. For instance, the United States Supreme Court has recently modified some tests used by the United States Patent and Trademark Office (USPTO) in granting patents during the past 20 years which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of challenge of any patents we obtain or license. In addition, the United States recently enacted sweeping changes to the United States patent system under the Leahy-Smith America Invents Act (“AIA”), including changes that transition the United States from a “first-to-invent” system to a “first to file” system and alter the processes for challenging issued patents |
| ● | More patent applications are filed each year resulting in longer delays in getting patents issued by the USPTO. |
| ● | Federal courts are becoming more crowded, and as a result, patent enforcement litigation is taking longer. |
| ● | As patent enforcement becomes more prevalent, it may become more difficult for us to voluntarily license our patents. |
| ● | The need to educate potential customers about our patent rights and our product and service capabilities; |
| ● | Customers’ willingness to invest potentially substantial resources and modify their network infrastructures to take advantage of our products; |
| ● | Customers’ budgetary constraints; |
| ● | The timing of customers’ budget cycles; and |
| ● | Delays caused by customers’ internal review processes. |
| ● | Long sales cycles may increase the risk that our financial resources are exhausted before we are able to generate significant revenue. |
| ● | power loss, transmission cable cuts and other telecommunications failures; |
| ● | damage or interruption caused by fire, earthquake, and other natural disasters; |
| ● | computer viruses or software defects; and |
| ● | physical or electronic break-ins, sabotage, intentional acts of vandalism, terrorist attacks and other events beyond our control |
| ● | developments in any then-outstanding litigation; |
| ● | quarterly variations in our operating results; |
| ● | large purchases or sales of common stock or derivative transactions related to our stock; |
| ● | actual or anticipated announcements of new products or services by us or competitors; |
| ● | general conditions in the markets in which we compete; and |
| ● | general economic and financial conditions |
| · | the outcome of actions to enforce our intellectual property rights currently in progress or that we may undertake in the future, and the timing thereof; |
| · | the amount and timing of receipt of license fees from potential infringers, licensees or customers; |
| · | the rate of adoption of our patented technologies; |
| · | the number of new license arrangements we may execute, or that may expire, within a particular period and the scope of those licenses, including the number of our patents which are licensed, the extent of prior infringement of our patent rights, royalty rates, timing of payment obligations, expiration date etc; |
| · | the success of a licensee in selling products that use our patented technologies; and |
| · | the amount and timing of expenses related to our patent filings and enforcement proceedings, including litigation, related to our intellectual property rights. |
| ● | A staggered Board of Directors : This means that only one or two directors (since we have a five-person Board of Directors) will be up for election at any given annual meeting. This has the effect of delaying the ability of stockholders to effect a change in control of us because it would take two annual meetings to effectively replace a majority of the Board of Directors. |
| ● | Blank check preferred stock : Our Board of Directors has the authority to establish the rights, preferences and privileges of our 10,000,000 authorized, but unissued, shares of preferred stock. Therefore, this stock may be issued at the discretion of our Board of Directors with preferences over your shares of our common stock in a manner that is materially dilutive to you. In addition, blank check preferred stock can be used to create a “poison pill” which is designed to deter a hostile bidder from buying a controlling interest in our stock without the approval of our Board of Directors. We have not adopted such a “poison pill;” but our Board of Directors has the ability to do so in the future, very rapidly and without stockholder approval. |
| ● | Advance notice requirements for director nominations and for new business to be brought up at stockholder meetings : Stockholders wishing to submit director nominations or raise matters to a vote of the stockholders must provide notice to us within very specific date windows and in very specific form in order to have the matter voted on at a stockholder meeting. This has the effect of giving our Board of Directors and management more time to react to stockholder proposals generally and could also have the effect of disregarding a stockholder proposal or deferring it to a subsequent meeting to the extent such proposal is not raised properly. |
| ● | No stockholder actions by written consent : No stockholder or group of stockholders may take actions rapidly and without prior notice to our Board of Directors and management or to the minority stockholders. Along with the advance notice requirements described above, this provision also gives our Board of Directors and management more time to react to proposed stockholder actions. |
| ● | Super majority requirement for stockholder amendments to the By-laws : Stockholder proposals to alter or amend our By-laws or to adopt new By-laws can only be approved by the affirmative vote of at least 66 2/3% of the outstanding shares of our common stock. |
| ● | No ability of stockholders to call a special meeting of the stockholders : Only the Board of Directors or management can call special meetings of the stockholders. This could mean that stockholders, even those who represent a significant percentage of our shares of common stock, may need to wait for the annual meeting before nominating directors or raising other business proposals to be voted on by the stockholders. |
|
Exhibit Number
|
Description
|
|
31.1
|
Certification of the President and Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
31.2
|
Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
32.1*
|
Certification of the President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
32.2*
|
Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
101**
|
Interactive Data Files
|
|
|
|
| * | This exhibit is furnished herewith, but not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section. Such certifications will not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except to the extent that we explicitly incorporate them by reference. |
|
|
VIRNETX HOLDING CORPORATION
|
||
|
|
|
||
|
|
By:
|
/s/ Kendall Larsen
|
|
|
|
|
Name
|
Kendall Larsen
|
|
|
|
|
|
|
|
|
|
Chief Executive Officer (Principal Executive Officer)
|
|
|
By:
|
/s/ Richard H. Nance
|
|
|
|
|
Name
|
Richard H. Nance
|
|
|
|
|
|
|
|
|
|
Chief Financial Officer (Principal Financial Officer and
|
|
|
|
|
|
|
|
|
|
Principal Accounting Officer)
|
|
Date: May 9, 2014
|
|
|
|
|
Exhibit Number
|
Description
|
|
Certification of the President and Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
Certification of the President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
101**
|
Interactive Data Files
|
|
|
|
| * | This exhibit is furnished herewith, but not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section. Such certifications will not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except to the extent that we explicitly incorporate them by reference. |
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|